These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 27109271)

  • 41. Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings.
    Cambiano V; Bertagnolio S; Jordan MR; Lundgren JD; Phillips A
    J Infect Dis; 2013 Jun; 207 Suppl 2():S57-62. PubMed ID: 23687290
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Finding patients eligible for antiretroviral therapy using TB services as entry point for HIV treatment.
    Bwire R; Nagelkerke NJ; Borgdorff MW
    Trop Med Int Health; 2006 Oct; 11(10):1567-75. PubMed ID: 17002731
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Antiretroviral therapy of HIV infection].
    Imamura A
    Nihon Rinsho; 2012 Apr; 70(4):601-6. PubMed ID: 22568140
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiretroviral therapy needs: the effect of changing global guidelines.
    Stanecki K; Daher J; Stover J; Beusenberg M; Souteyrand Y; García Calleja JM
    Sex Transm Infect; 2010 Dec; 86 Suppl 2(Suppl_2):ii62-6. PubMed ID: 21106517
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does a significant reduction in malaria risk make lopinavir/ritonavir-based ART cost-effective for children with HIV in co-endemic, low-resource settings?
    Ahmed BS; Phelps BR; Reuben EB; Ferris RE
    Trans R Soc Trop Med Hyg; 2014 Jan; 108(1):49-54. PubMed ID: 24300443
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Unresolved antiretroviral treatment management issues in HIV-infected children.
    Heidari S; Mofenson LM; Hobbs CV; Cotton MF; Marlink R; Katabira E
    J Acquir Immune Defic Syndr; 2012 Feb; 59(2):161-9. PubMed ID: 22138766
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiretroviral treatment in resource-poor settings: a view from India.
    Vajpayee M; Kaushik S; Mojumdar K; Sreenivas V
    Indian J Med Sci; 2007 Jul; 61(7):390-7. PubMed ID: 17611344
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations.
    Richardson ET; Grant PM; Zolopa AR
    Antiviral Res; 2014 Mar; 103():88-93. PubMed ID: 24374148
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Forecasting the global demand for HIV monitoring and diagnostic tests: A 2016-2021 analysis.
    Habiyambere V; Dongmo Nguimfack B; Vojnov L; Ford N; Stover J; Hasek L; Maggiore P; Low-Beer D; Pérez Gonzàlez M; Edgil D; Williams J; Kuritsky J; Hargreaves S; NeSmith T
    PLoS One; 2018; 13(9):e0201341. PubMed ID: 30231022
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The HIV treatment cascade in acutely infected people: informing global guidelines.
    Rutstein SE; Sellers CJ; Ananworanich J; Cohen MS
    Curr Opin HIV AIDS; 2015 Nov; 10(6):395-402. PubMed ID: 26371460
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Research progress on the association between HIV antiretroviral therapy and the outbreak].
    Ding ZX; Lu ZZ; Wang L; Wang N; Peng ZH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2020 May; 41(5):794-798. PubMed ID: 32447927
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Commentary: scaling up HIV treatment in resource-limited countries: the challenge of staff shortages.
    Laurent C
    J Public Health Policy; 2011 May; 32(2):211-8. PubMed ID: 21346787
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preferred antiretroviral drugs for the next decade of scale up.
    Andrieux-Meyer I; Calmy A; Cahn P; Clayden P; Raguin G; Katlama C; Vitoria M; Levin A; Lynch S; Goemaere E; Ford N;
    J Int AIDS Soc; 2012 Sep; 15(2):17986. PubMed ID: 23010379
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiretrovirals reach more people in poor countries but many still lack access, UNAIDS says.
    Zarocostas J
    BMJ; 2008 Jun; 336(7656):1270. PubMed ID: 18535056
    [No Abstract]   [Full Text] [Related]  

  • 55. Which patients first? Setting priorities for antiretroviral therapy where resources are limited.
    McGough LJ; Reynolds SJ; Quinn TC; Zenilman JM
    Am J Public Health; 2005 Jul; 95(7):1173-80. PubMed ID: 15983271
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Towards an ideal antiretroviral regimen for the global HIV epidemic.
    Grinsztejn B; Coelho LE; Luz PM; Veloso VG
    J Virus Erad; 2017 Jul; 3(3):111-116. PubMed ID: 28758017
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug interactions and the role of pharmacokinetic trials in guiding choices in first-line HIV therapy in low-income and middle-income countries.
    Seden K; Boffito M; Khoo S
    Curr Opin HIV AIDS; 2017 Jul; 12(4):377-382. PubMed ID: 28570369
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIV epidemiology in the WHO Eastern Mediterranean region: a multicountry programme review.
    Mugisa B; Sabry A; Hutin Y; Hermez J
    Lancet HIV; 2022 Feb; 9(2):e112-e119. PubMed ID: 35120632
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Accelerating access and scale-up of optimized antiretroviral therapy in low-income and middle-income countries: results of a coordinated end-to-end approach.
    Harris EL; Blumer K; Perez Casas C; Ferris D; Amole C; Doherty M; Auton M
    AIDS; 2021 Dec; 35(Suppl 2):S165-S171. PubMed ID: 34848583
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of peptide inhibitors of HIV transmission.
    Shi S; Nguyen PK; Cabral HJ; Diez-Barroso R; Derry PJ; Kanahara SM; Kumar VA
    Bioact Mater; 2016 Dec; 1(2):109-121. PubMed ID: 29744399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.